Dr. Cheng completed her MD at Beijing Medical University, Beijing, China in 1987 and MSc. at the University of Calgary in Molecular Oncology in 1991. She obtained board certification in Internal Medicine in 2001 and Medical Oncology in 2003 at the University of Calgary. Dr. Cheng joined the Tom Baker Cancer Centre in 2003 subspecialized in Cutaneous and GU cancers.
Area of Focus
- Cutaneous and Genitourinary malignancies
Summary of Research
Dr. Cheng is an expert in melanoma, other cutaneous malignancies, testicular germ cell cancer, and other GU cancers. She is recognized as a national expert in immune-oncology and a productive clinical trialist. She has led two multi-centre clinical trials in Canada and has contributed to several key oncology drug developments in recent years. Her key research interest is in the area of immunotherapy for cancers, especially melanoma focusing on disease characteristics, treatment outcome, and clinical and biological predictors for response and toxicity. She is experienced in database research and translational research. Currently, she is investigating UV-mediated melanomagenesis and molecular signatures of UV mutagenesis in melanoma. She is particularly interested in the distinct pathogenic pathway leading to the development of uveal melanoma and potential molecular markers for recurrence and survival in uveal melanoma. Dr. Cheng is leading the Fellowship training program in Immuno-oncology and Cutaneous Malignancies and this program has intake for post-graduate trainees both nationally and internationally.
Area Of Focus
- Cutaneous and Genitourinary malignancies
Summary Of Research
Dr. Cheng is an expert in melanoma, other cutaneous malignancies, testicular germ cell cancer, and other GU cancers. She is recognized as a national expert in immune-oncology and a productive clinical trialist. She has led two multi-centre clinical trials in Canada and has contributed to several key oncology drug developments in recent years. Her key research interest is in the area of immunotherapy for cancers, especially melanoma focusing on disease characteristics, treatment outcome, and clinical and biological predictors for response and toxicity. She is experienced in database research and translational research. Currently, she is investigating UV-mediated melanomagenesis and molecular signatures of UV mutagenesis in melanoma. She is particularly interested in the distinct pathogenic pathway leading to the development of uveal melanoma and potential molecular markers for recurrence and survival in uveal melanoma. Dr. Cheng is leading the Fellowship training program in Immuno-oncology and Cutaneous Malignancies and this program has intake for post-graduate trainees both nationally and internationally.